Study looks at price trends for popular brand-name drugs
In an evaluation of 49 top-selling brand-name drugs, 28 of the drugs available since 2012 saw an increase in insurer and out-of-pocket costs of more than 50 percent by 2017 and 16 more than doubled in price, according to a study reported Friday in JAMA Network Open. The study examined pharmacy claims data for more than 35 million people with private pharmaceutical insurance.
Related News Articles
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The White House May 18 announced an expansion of TrumpRx.gov, which now features more than 600 generic drugs. The direct-to-consumer platform serves as a hub…
Headline
The Department of Health and Human Services yesterday announced an action plan on psychiatric prescribing, including efforts to initiate …
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The administration Apri 23 reached a most-favored-nation drug pricing agreement with Regeneron, the maker of the popular cholesterol medicine Praluent. This is…
Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…